Starting Ozempic, Wegovy, Mounjaro or Zepbound: What to Expect in Your First Month

She arrived with a new pen in a cool bag, a printed leaflet she had not yet read, and a nervous laugh. "My doctor said to start next Monday," a woman in her thirties told me. "What am I actually in for?" Starting Ozempic, Wegovy, Mounjaro or Zepbound is a big step, and almost nobody has the whole picture on day one.

This article walks through the first month: what these medicines are, why the first dose is deliberately small, what you may feel, and how to set up your routine. The details of your own plan belong to your prescriber, so treat this as background to bring to that conversation.

Same medicine, different names

Ozempic and Wegovy both contain semaglutide, made by Novo Nordisk. Mounjaro and Zepbound both contain tirzepatide, made by Eli Lilly. The difference is the approved purpose. In the US, Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy and Zepbound are labeled for weight management. Ozempic is also labeled to reduce heart and kidney risks in certain people with type 2 diabetes, and Wegovy for heart risk reduction in certain adults. Your prescriber chooses the product that fits your health situation and what your insurance or health service will cover.

All of them copy natural gut hormones that signal fullness and slow the stomach's emptying. In the UK, the NHS notes that tirzepatide can be prescribed for type 2 diabetes or for weight loss, with BMI eligibility rules for weight loss that depend on who prescribes it.

What to expect when starting Ozempic, Wegovy, Mounjaro or Zepbound

The first thing to know is that your first dose is not a treatment dose. The labels start low and climb in steps so your body can adjust.

• Ozempic: 0.25 mg once weekly for 4 weeks, then 0.5 mg. Further increases are possible after at least 4 weeks on each dose, depending on blood sugar control.
• Wegovy injection: 0.25 mg weekly, then 0.5 mg, 1 mg and 1.7 mg, with a step about every 4 weeks. From week 17, the maintenance dose is 2.4 mg, with 1.7 mg an alternative.
• Mounjaro: 2.5 mg weekly to start. If more blood sugar control is needed, the dose can go up in 2.5 mg steps after at least 4 weeks on the current dose, to a maximum of 15 mg in adults.
• Zepbound: 2.5 mg weekly for 4 weeks, then 5 mg. After that, increases come in 2.5 mg steps, with at least 4 weeks on each dose, to a maximum of 15 mg.

The Zepbound label says 2.5 mg is for starting treatment only and is not the maintenance dose. These schedules are what the labels describe in general. Your own plan may be slower, and you should follow your prescriber's instructions, not a table in an article. If a dose is not tolerated, the Wegovy label notes that the next increase can be delayed.

So in your first month you will probably take four weekly doses of the lowest strength. Many people notice a smaller appetite, earlier fullness and less interest in snacking. Others notice very little at first. A quiet first month does not mean the medicine is failing, because the dose is meant to be a gentle introduction.

Side effects in the first weeks

Nausea, diarrhea, constipation and vomiting are the usual early effects. The Zepbound label reports that most nausea, vomiting and diarrhea happened during dose increases and lessened over time, and that the slowing of the stomach is strongest after the first dose. In the Wegovy trials, nausea affected 44% of people on the 2.4 mg dose compared with 16% on placebo, and in the Zepbound trials 25% to 29% compared with 8%. Those figures reflect full escalation, so the first month at a low dose may be gentler.

A few habits help most people:

• Eat smaller portions and stop when you feel full.
• Limit alcohol, which the NHS says can make nausea and vomiting worse.
• Drink fluids through the day. Dehydration can strain the kidneys, and all three US labels carry warnings about kidney injury linked to fluid loss.
• Build fiber up gradually to prevent constipation.

For a fuller guide to managing these, see my companion article on GLP-1 side effects on this site. And please do not stop or change your dose without speaking to your prescriber.

Setting up your routine

Pick a day. The injection is once weekly, on the same day. For the tirzepatide products the label allows it at any time of day, with or without food. Ozempic is also taken with or without meals. If you need to change your day, the tirzepatide labels say doses should be at least 3 days (72 hours) apart, and the Ozempic label says more than 48 hours apart.

Choose a site and rotate it. The labels list the abdomen, thigh, or back of the upper arm (when someone else injects you for tirzepatide). Use a different spot each week.

Know your missed-dose rule. It differs between products. For tirzepatide, a missed dose can be given within 4 days (96 hours), and after that you skip it and carry on. For Ozempic, the window is 5 days. Wegovy has its own instructions. Read your leaflet, and call your pharmacist if you are unsure. Never double up.

Store the pen properly. For Ozempic, the label says unused pens belong in the refrigerator at 36 to 46 °F (2 to 8 °C) and should never be frozen, and a pen in use can be kept for 56 days either in the fridge or at room temperature. Other products have different limits, so follow the storage section of your own pen's instructions. Never share a pen with anyone, even if you change the needle.

Oral version. Wegovy also comes as a daily tablet. The Wegovy label says to take the tablet on an empty stomach with no more than 4 ounces of water and wait at least 30 minutes before eating, drinking or taking other tablets.

What to tell your prescriber and pharmacist before you start

• Thyroid history. These medicines carry a boxed warning for thyroid tumors seen in rodents. They are contraindicated if you or your family have had medullary thyroid cancer or MEN 2.
• Pancreas or gallbladder problems. The labels warn about pancreatitis and gallbladder disease.
• Severe stomach problems. Zepbound and Ozempic are not recommended in severe gastroparesis (a stomach that empties very slowly).
• Diabetes medicines. Insulin and sulfonylureas raise the risk of low blood sugar when combined with these medicines, so doses may need to be reduced.
• Other tablets. Because the stomach empties more slowly, absorption of some oral medicines may change, so your pharmacist should review your full list.
• Birth control and pregnancy. The Zepbound label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. The UK regulator (MHRA) gives the same advice for tirzepatide. The Wegovy label advises stopping at least 2 months before a planned pregnancy, and the MHRA suggests at least one month for tirzepatide.
• Eye disease. If you have diabetic retinopathy, the Wegovy label says you should be monitored.
• Planned surgery or sedation. Rare reports of lung aspiration during anesthesia mean your team should know.

Protecting your muscle and your nutrition

Eating less means you must work harder to eat well. A joint nutrition advisory reports that in the STEP 1 trial of semaglutide, average weight loss was 13.6 kg, and about 5.3 kg of it (38%) was lean mass, which includes muscle. It proposes aiming for roughly 1.2 to 1.6 grams of protein per kilogram of body weight daily during active weight loss, and notes that protein alone will not preserve muscle without resistance training. When your appetite is small, put protein first on the plate, such as eggs, fish, beans, yogurt or chicken. Ask your doctor what protein level suits you, especially if you have kidney disease.

The NIDDK suggests strength training twice a week for people with diabetes, and the same habit makes sense for anyone losing weight. Body weight exercises, resistance bands or a simple weights routine will do.

Where you get the medicine matters

Supply problems in recent years pushed many people to compounded or online products. The FDA states that compounded drugs are not FDA approved. It has received reports of dosing errors that led to hospitalization, counterfeit Ozempic, and products labeled "for research purposes" that were sold for human use. Red flags include prices that seem too good to be true, no prescription, no licensed doctor to ask questions, spelling mistakes on labels and medicine that arrives warm. The MHRA similarly notes that legitimate products are pre-filled pens, and that powder to be mixed in vials is not authorized.

Get a prescription from a licensed clinician and fill it at a state-licensed pharmacy (UK readers should check the General Pharmaceutical Council register). If something looks different from last time, ask a pharmacist before you inject it.

Questions to ask your doctor or pharmacist

• Which product and dose am I starting on, and what is the planned schedule for increases?
• What do I do if I miss a dose of this particular pen?
• How should I store it, and how long can it stay out of the fridge?
• Which side effects mean I should call you straight away?
• Do any of my current medicines or supplements need to change?
• What should I eat, and how much protein is right for me?
• When will we review how it is working, and what is the plan if I want to stop?

If you'd like the full guide, my book The Pharmacist's GLP-1 Guide goes deeper into starting these medicines safely, managing side effects and protecting your muscle.

Sources

• U.S. Food and Drug Administration. WEGOVY (semaglutide) prescribing information, revised 03/2026
• U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) prescribing information, revised 04/2026
• U.S. Food and Drug Administration. OZEMPIC (semaglutide) prescribing information, revised 05/2026
• Eli Lilly. MOUNJARO (tirzepatide) prescribing information (FDA label text, revised 08/2026)
• U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
• NHS. Tirzepatide (Mounjaro)
• NHS. Semaglutide
• The Pharmaceutical Journal. MHRA urges women taking weight loss drugs to use effective contraception (June 2025, reporting MHRA advice)
• National Institute of Diabetes and Digestive and Kidney Diseases. Diet, eating and physical activity (diabetes)
• Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity. 2025;33(8):1475-1503.